HIV-1 envelope glycoproteins (Envs) mediate virus entry by fusing the viral and target cell membranes, a multi-step process that represents an attractive target for inhibition. Entry inhibitors with broad-range activity against diverse isolates of HIV-1 may be extremely useful as lead compounds for the development of therapies or prophylactic microbicides. To facilitate the identification of such inhibitors, we have constructed a cell-cell fusion system capable of simultaneously monitoring inhibition efficiency and specificity. In this system, effector cells stably express a tetracycline-controlled transactivator (tTA) that enables tightly inducible expression of both HIV-1 Env and the Renilla luciferase (R-Luc) reporter protein. Target cel...
Entry of human immunodeficiency virus type 1 (HIV-1) into target cells is mediated by its envelope p...
Therapeutic strategies aimed at inhibiting human immunodeficiency virus type 1 (HIV-1) replication e...
Broadly cross-reactive, neutralizing human monoclonal antibodies, including 2F5, 2G12, 4E10 and IgG1...
Human Immunodeficiency Virus-1 (HIV-1) entry is dependent on the envelope glycoprotein (Env) that is...
HIV-1 entry and fusion with target cells is an important target for antiviral therapy. However, a fe...
HIV-1 entry and fusion with target cells is an important target for antiviral therapy. However, a fe...
The discovery of HIV-1 integrase inhibitors has been enabled by high-throughput screening and ration...
The discovery of HIV-1 integrase inhibitors has been enabled by high-throughput screening and ration...
The discovery of HIV-1 integrase inhibitors has been enabled by high-throughput screening and ration...
Objectives: HIV-1 initiates infection by fusing with CD4+ lymphocytes or macrophages, mediated by th...
Most research on HIV transmission and microbicides focuses on the inhibition of cell-free virus (CFV...
Objectives: HIV-1 initiates infection by fusing with CD4+ lymphocytes or macrophages, mediated by th...
HIV entry into target cells requires the interaction of the HIV envelope glycoprotein (Env) with a p...
HIV entry into target cells requires the interaction of the HIV envelope glycoprotein (Env) with a p...
Includes bibliographical references (p. 25-27).It is well established that HIV relies on both the vi...
Entry of human immunodeficiency virus type 1 (HIV-1) into target cells is mediated by its envelope p...
Therapeutic strategies aimed at inhibiting human immunodeficiency virus type 1 (HIV-1) replication e...
Broadly cross-reactive, neutralizing human monoclonal antibodies, including 2F5, 2G12, 4E10 and IgG1...
Human Immunodeficiency Virus-1 (HIV-1) entry is dependent on the envelope glycoprotein (Env) that is...
HIV-1 entry and fusion with target cells is an important target for antiviral therapy. However, a fe...
HIV-1 entry and fusion with target cells is an important target for antiviral therapy. However, a fe...
The discovery of HIV-1 integrase inhibitors has been enabled by high-throughput screening and ration...
The discovery of HIV-1 integrase inhibitors has been enabled by high-throughput screening and ration...
The discovery of HIV-1 integrase inhibitors has been enabled by high-throughput screening and ration...
Objectives: HIV-1 initiates infection by fusing with CD4+ lymphocytes or macrophages, mediated by th...
Most research on HIV transmission and microbicides focuses on the inhibition of cell-free virus (CFV...
Objectives: HIV-1 initiates infection by fusing with CD4+ lymphocytes or macrophages, mediated by th...
HIV entry into target cells requires the interaction of the HIV envelope glycoprotein (Env) with a p...
HIV entry into target cells requires the interaction of the HIV envelope glycoprotein (Env) with a p...
Includes bibliographical references (p. 25-27).It is well established that HIV relies on both the vi...
Entry of human immunodeficiency virus type 1 (HIV-1) into target cells is mediated by its envelope p...
Therapeutic strategies aimed at inhibiting human immunodeficiency virus type 1 (HIV-1) replication e...
Broadly cross-reactive, neutralizing human monoclonal antibodies, including 2F5, 2G12, 4E10 and IgG1...